system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Adaptor Proteins, Signal Transducing, Adult, Aged, Antineoplastic Agents, Carcinoma, DNA, DNA Methylation, Drug Resistance, Neoplasm, Female, Humans, Male, Microsatellite Repeats, Middle Aged, MutL Protein Homolog 1, Nuclear Proteins, Ovarian Neoplasms, Platinum Compounds, Promoter Regions, Genetic, Sequence Analysis, DNA.
user
Is a change in promoter methylation of hMLH1 a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer? Context: Acquired resistance to platinum-based chemotherapy (Pt-chemo) is a major problem for improving the prognosis for patients with advanced epithelial ovarian cancer (EOC). However, the molecular mechanism of acquired resistance to Pt-chemo is not well understood. hMLH1 promoter methylation (hMLH1 MET) and hMLH1 protein expression was examined in 36 paired samples of primary and secondary resected tumors by methylation-specific polymerase chain reaction (PCR). No primary tumors exhibited hMLH1 MET, while 56.3% of secondary tumors showed hMLH1 MET. Moreover, no significant correlation was observed between hMLH1 MET and histological subtype, while hMLH1 MET was significantly greater (p < 0.001) in partially responsive secondary tumors compared with no change or progressive disease, and hMLH1 MET also occurred more frequently (p = 0.059) in tumors treated with four or more courses of Pt-chemo.
assistant
A change in hMLH1 MET is a major molecular cause of acquired resistance to Pt-chemo in EOC. Final Decision: yes